Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model

American Journal of Nephrology

Volumn 24, Issue 2, 2004, Pages 242-249

  Zhou, Xiaoyan ^a   Ono, Hidehiko ^a   Ono, Yuko ^a   Frohlich, Edward D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Aldosterone antagonism; Angiotensin converting enzyme inhibition; Eplerenone; Glomerular dynamics; L NAME; Lisinopril; Nephrosclerosis; Proteinuria

Indexed keywords

ALDOSTERONE ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; EPLERENONE; LISINOPRIL; N(G) NITROARGININE METHYL ESTER; TAP WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; GLOMERULUS FILTRATION; HISTOPATHOLOGY; HYPERTENSION; KIDNEY ARTERY; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY TUBULE; MALE; MEAN ARTERIAL PRESSURE; NEPHROSCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; PUNCH BIOPSY; RAT; RAT STRAIN; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

ALDOSTERONE ANTAGONISTS; ANIMALS; HEMODYNAMIC PROCESSES; KIDNEY GLOMERULUS; MALE; NEPHROSCLEROSIS; NG-NITROARGININE METHYL ESTER; PROTEINURIA; RATS; RATS, INBRED SHR; SPIRONOLACTONE;

EID: 1842474802     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077396     Document Type: Article

References (36)

1. Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH: The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 1994;45:403-410.
2. Ma L, Fogo AB: Role of angiotensin II in glomerular injury. Semin Nephrol 2001;21:544-553.
3. Cao Z, Cooper ME: Role of angiotensin II in tubulointerstitial injury. Semin Nephrol 2001;21:554-562.
4. Ono H, Ono Y, Frohlich ED: Nitric oxide synthase inhibition in spontaneously hypertension rats: Systemic, renal, and glomerular hemodynamics. Hypertension 1995;27:249-255.
5. Ono H, Ono Y, Takanohashi A, Matsuoka H, Frohlich ED: Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats. Hypertension 2001;38:1300-1306.
6. Zanchi A, Schaad NC, Osterheld MC, Grouzmann E, Nussberger J, Brunner HR, Waeber B: Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. Am J Physiol 1995;268:H2267-H2273.
7. Wessels J, Peake P, Pussell BA, Macdonald GJ: Nitric oxide synthase inhibition in a spontaneously hypertensive rat model of diabetic nephropathy. Clin Exp Pharmacol Physiol 1997;24:451-453.
8. Kashiwagi M, Shinozaki M, Hirakata H, Tamaki K, Hirano T, Tokumoto M, Goto H, Kuda S, Fujishima M: Locally activated renin-angiotensin system associated with TGF-beta1 as a major actor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2000;11:616-624.
9. Ono H, Ono Y, Frohlich ED: ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertension rats. Hypertension 1996;27:176-183.
10. Francischetti A, Ono H, Frohlich ED: Reno-protective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1998;31:795-801.
11. Nakamura Y, Ono H, Zhou X, Frohlich ED: Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in Nω-nitro-l-arginine methyl ester/spontaneously hypertensive rats. Hypertension 2001;37:1262-1267.
12. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG: Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63:1791-1800.
13. Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996;98:1063-1068.
14. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-458.
15. Rocha R, Chander PN, Zuckerman A, Stier CT Jr: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999;33:232-237.
16. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK: Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-3878.
17. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000;58:1219-1227.
18. Hene RJ, Boer P, Koomans HA, Mees EJ: Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982;21:98-101.
19. Epstein M: Aldosterone and the hypertensive kidney: Its emerging role as a mediator of progressive renal dysfunction: A paradigm shift. J Hypertens 2001;19:829-842.
20. Epstein M: Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications. Am J Kidney Dis 2001;37:677-688.
21. Frohlich ED: Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension 1997;29:188-193.
22. Fritsch Neves M, Schiffrin EL: Aldosterone: A risk factor for vascular disease. Curr Hypertens Rep 2003;5:59-65.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
24. Falchuk KH, Berliner RW: Hydrostatic pressures in peritubular capillaries and tubules in the rat kidney. Am J Physiol 1971;220:1422-1426.
25. Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K, Ritz E: Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol. 2003;14:2833-2842.
26. Quinn SJ, Williams GH: Regulation of aldosterone secretion. Annu Rev Physiol 1988;50:409-426.
27. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-1026.
28. Epstein M, Buckalew V Jr, Martinez F, Altamirano J, Roniker B, Kleiman J, Krause S: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens 2002;15:24 A.
29. Arcos MI, Fujihara CK, Sesso A, de Almeida Prado EB, de Almeida Prado MJ, de Nucci G, Zatz R: Mechanisms of albuminuria in the chronic nitric oxide inhibition model. Am J Physiol 2000;279:F1060-F1066.
30. Sato A, Suzuki Y, Shibata H, Saruta T: Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. Hypertens Res 2000;23:25-31.
31. Struthers AD: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54.
32. Shiigai T, Shichiri M: Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001;37:477-483.
33. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-68.
34. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
35. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
36. Ono Y, Ono H, Frohlich ED: Hydrochlorothiazide exacerbates nitric oxide blockades nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens 1996;14:823-828.